drugset
drugset / Trial / NCT00760084

Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

NCT00760084 ↗

Phase 2 Completed 10 enrolled Eisai Inc.
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to provide decitabine to patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) who have completed participation per protocol in the DACO-018 study.

Timeline

Start
2005-07
Primary completion
2005-09
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule 20 mg/m2 Intravenous

Indications

acute myeloid leukemia myelodysplastic syndrome